Samir Chandrakant Patel - 10 Apr 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Reporting relationship: Director
Issuer ticker: KLRS
Reported as of: 10 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Apr 2025, 17:04:19 UTC
Prior SEC filing: 18 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Oxtoby, Attorney-in-Fact

Key filing fact

Samir Chandrakant Patel filed Form 4 for Kalaris Therapeutics, Inc. (KLRS) on 11 Apr 2025.

Key facts

This page summarizes Samir Chandrakant Patel's Form 4 filing for Kalaris Therapeutics, Inc. (KLRS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Apr 2025, 17:04.

Change

Previous filing in this sequence was filed on 18 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +18,000
Change %
Price: $0.000000
Shares after: 18,000
Date: 10 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $7.31
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.